Onco-Innovations signs LOI with Ifowonco for option, global license to LAG-3 small-molecule program
Reuters2026/08/19 22:40- Onco-Innovations signed a non-binding LOI with Ifowonco to negotiate an exclusive option and worldwide license for a LAG-3 small-molecule inhibitor program.
- Deal targets an oral LAG-3 immune checkpoint inhibitor platform, positioned as an alternative to intravenous monoclonal-antibody LAG-3 therapies.
- Parties plan to evaluate combinations with ONC010, aiming to pair DNA damage response inhibition with LAG-3 blockade across solid tumors.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Saving in the US, paying globally? Industry research warns: Trump’s push to lower drug prices could instead incentivize pharmaceutical companies to raise prices overseas
A study published in The Lancet indicates that Trump's efforts to lower drug prices in the United States may force pharmaceutical companies to raise prices internationally or exit certain markets, potentially leading to a significant reduction in the approximately $11.6 billion saved annually by Medicare.
Franco-Nevada buys A$170 million Bullabulling gold project royalty from Minerals 260
10-Yr Benchmark Govt Yields - Germany vs Other Nations
Crypto prices
More
